Evidence map›Paper›PMID 41479590›Full record

ArticleCase reports in oncology

Long-Term Control after Intermittent Reintroduction of Enfortumab Vedotin in Metastatic Urothelial Carcinoma: A Case Report.

Kenta Fujii, Suguru Shirotake, Shohei Yamamura, Daisuke Igarashi, Takayuki Takahashi, Yuta Umezawa, Kimiharu Takamatsu, Masayuki Hagiwara, Go Kaneko, Masafumi Oyama

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kenta FujiiDepartment of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka, Japan.
Suguru ShirotakeDepartment of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka, Japan.
Shohei YamamuraDepartment of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka, Japan.
Daisuke IgarashiDepartment of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka, Japan.
Takayuki TakahashiDepartment of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka, Japan.
Yuta UmezawaDepartment of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka, Japan.
Kimiharu TakamatsuDepartment of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka, Japan.
Masayuki HagiwaraDepartment of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka, Japan.
Go KanekoDepartment of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka, Japan.
Masafumi OyamaDepartment of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Enfortumab vedotin (EV), an antibody-drug conjugate targeting Nectin-4, has become a standard treatment option for metastatic urothelial carcinoma (mUC) following failure of platinum-based chemotherapy and immune checkpoint inhibitors. However, adverse events (AEs) such as skin toxicity often necessitate dose modification or temporary discontinuation. Case Presentation: We report the case of a 72-year-old woman with mUC who achieved a long-term partial response to EV despite experiencing grade 2 skin toxicity that required temporary treatment interruption. After symptom resolution, EV was successfully reintroduced at a reduced dose, and clinical response was maintained. Conclusion: Temporary discontinuation of EV due to AEs followed by intermittent reintroduction resulted in long-term disease control in this patient with mUC. This case suggests that rechallenging EV after treatment interruption may be a feasible approach in selected patients, underscoring the importance of careful AE management in real-world practice.

Indexed as

Adverse event managementDurable disease controlEnfortumab vedotinIntermittent reintroductionMetastatic urothelial carcinoma

Identifiers

PMID41479590
PMCPMC12755892

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.